Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.51 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.48 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.48 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.48 |
| ▸ | KLK7 | P49862 | 2/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | EPOR | P19235 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7511729 | 0.95 | MAPT (0.53) | MAPTFOLH1TPSAB1TPSD1TPSG1 | |
| SCHEMBL8777364 | 0.89 | FOLH1 (0.50) | MAPTFOLH1TPSAB1TPSD1TPSG1 | |
| SCHEMBL4541834 | 0.88 | MAPT (0.56) | MAPTFOLH1TPSAB1TPSD1TPSG1 | |
| SCHEMBL1882392 | 0.88 | MAPT (0.56) | MAPTFOLH1TPSAB1TPSD1TPSG1 | |
| SCHEMBL464495 | 0.85 | TGM2 (0.53) | MAPTFOLH1TPSAB1TPSD1TPSG1 | |
| SCHEMBL31490054 | 0.85 | HTT (0.54) | MAPTFOLH1TPSAB1TPSD1TPSG1 | |
| SCHEMBL15227896 | 0.83 | MAPT (0.50) | MAPTFOLH1TPSAB1TPSD1TPSG1 | |
| SCHEMBL6840857 | 0.83 | SMN1; SMN2 (0.52) | MAPTHTT | |
| SCHEMBL7156418 | 0.81 | SMN1; SMN2 (0.52) | MAPTHTT | |
| SCHEMBL24945922 | 0.80 | MAPT (0.54) | MAPTFOLH1TPSAB1TPSD1TPSG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1259532-B1 | BILE ACIDS CONJUGATES WITH METAL ION CHELATES AND THE USE THEREOF | BRACCO IMAGING SPA (IT) | 2005-05-04 | — | — | EP | disclosed |
| US-6803030-B2 | CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING | BRACCO IMAGING S.P.A. (IT) | 2004-10-12 | — | — | US | disclosed |
| US-20030113265-A1 | Bile acids conjugates with metal ion chelates and the use thereof | BRACCO IMAGING S.P.A. (IT) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030113265-A1 | Bile acids conjugates with metal ion chelates and the use thereof | SLC10A2, SLC10A1, NR1H4 | MAPT 469/4885FOLH1 179/4885TPSAB1 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.